“[F]irst-line treatment with zanidatamab plus chemotherapy demonstrated rapid and durable antitumor activity with promising survival outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma,” according to the study authors.
Combining zanidatamab-hrii (Ziihera) with chemotherapy as frontline treatment produced clinically meaningful and enduring activity in a small cohort of patients with HER2-positive advanced gastroesophageal adenocarcinoma, according to primary results from a phase 2 study (NCT03929666) published in Lancet Oncology.1
The study treatment yielded a confirmed objective response rate (ORR) of 76.2% (95% CI, 60.5%-87.9%) among 42 evaluable patients, which included complete responses (CRs) in 3 patients (7%) and partial responses (PRs) in 29 (69%). The median duration of response (DOR) was 18.7 months (95% CI, 10.4-44.1), and the post hoc median time to first response was 1.3 months (IQR, 1.3-1.4).
Data showed a median progression-free survival (PFS) of 12.5 months (95% CI, 8.2-21.8), with estimated PFS rates of 57% (95% CI, 40%-70%) at 12 months and 31% (95% CI, 17%-46%) at 24 months. Additionally, treatment elicited a median overall survival (OS) of 36.5 months (95% CI, 23.6-not estimable [NE]), a 12-month OS rate of 87% (95% CI, 72%-94%), and a 24-month OS rate of 65% (95% CI, 49%-77%).
“[F]irst-line treatment with zanidatamab plus chemotherapy demonstrated rapid and durable antitumor activity with promising survival outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma. Zanidatamab plus chemotherapy in the first-line setting was well tolerated with a manageable safety profile when incorporating antidiarrheal prophylaxis in the first 7 days of treatment,” lead study author Elena Elimova, MD, from the Department of Gastrointestinal Medical Oncology at Princess Margaret Cancer Centre in Toronto, Ontario, Canada, wrote with coauthors in the publication.1 “If these results are confirmed in a large-scale, randomized, phase 3 trial, zanidatamab could represent a substantial advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.”
In the open-label, multi-center phase 2 study, patients received zanidatamab in combination with capecitabine plus oxaliplatin (CAPOX), 5-fluorouracil (5-FU) plus cisplatin (FP), or leucovorin plus 5-FU and oxaliplatin (mFOLFOX6). In the CAPOX and FP groups, patients received zanidatamab at 30 mg/kg, 1800 mg with a weight of less than 70 kg, or 2400 mg with a weight of 70 kg or higher every 3 weeks. In the mFOLFOX6 group, patients received zanidatamab at 20 mg/kg, 1200 mg with a body weight under 70 kg, or 1600 mg with a weight of at least 70 kg every 2 weeks.
In part 1 of the trial, investigators evaluated the safety and tolerability of zanidatamab plus chemotherapy to determine a recommended phase 2 dose; the primary end points of this part were dose-limiting toxicities and dose reductions. In part 2 of the trial, the primary end point was investigator-assessed confirmed ORR per RECIST v1.1 criteria. Secondary efficacy endpoints across parts 1 and 2 of the trial included disease control rate, DOR, clinical benefit rate, PFS, and OS.
Patients 18 years and older with unresectable, locally advanced, recurrent, or metastatic HER2-expressing gastroesophageal adenocarcinoma and measurable disease per RECIST v1.1 guidelines were eligible for enrollment on the trial.2 Other eligibility criteria included having an ECOG performance status of 0 or 1, adequate organ function, and adequate cardiac left ventricular function.
The median patient age was 58 years (IQR, 55-63), and most of the population was male (85%), White (61%), and not Hispanic (93%). Additionally, most patients had an ECOG performance status of 0 (57%), gastric anatomical subtype disease (41%), stage IV disease at initial diagnosis (83%), and measurable disease (93%). Prior neoadjuvant or adjuvant chemotherapy was reported in 11% of patients.
In a subgroup of patients with centrally confirmed HER2-positive disease (n = 41), zanidatamab-based therapy produced a confirmed ORR of 84% (n = 31/37; 95% CI, 68.0%-93.8%). Furthermore, the median PFS was 15.2 months (95% CI, 9.5-33.4) in this subgroup, and the median OS was 36.5 months (95% CI, 23.6-NE).
In a post hoc analysis of patients who enrolled on the trial before and after the implementation of antidiarrheal prophylaxis, 61% (n = 14/23; 95% CI, 38.5%-80.3%) and 95% (n = 18/19; 95% CI, 74.0%-99.9%) experienced confirmed responses. Those who received antidiarrheal prophylaxis experienced longer treatment duration and exposure.
Treatment-related adverse effects (TRAEs) affected 100% of patients, with the most common grade 3/4 TRAEs consisting of diarrhea (39%) and hypokalemia (22%). Additionally, 17% of patients had serious TRAEs, the most common of which was diarrhea (7%).
The median duration of grade 1/2 or grade 3 diarrhea was 6.5 days (IQR, 2-29) and 3 days (IQR, 2-5), respectively, among patients who enrolled on the trial before the implementation of antidiarrheal prophylaxis. The median durations were 3 days (IQR, 2-13) and 4.5 days (IQR, 3-8) among those who entered the trial following the implementation of antidiarrheal prophylaxis.
References
Elimova E, Ajani J, Burris H, et al. Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study. Lancet Oncol. 2025;26(7):847-859. doi:10.1016/S1470-2045(25)00287-6
A safety and efficacy study of ZW25 (Zanidatamab) plus combination chemotherapy in HER2-expressing gastrointestinal cancers, including gastroesophageal adenocarcinoma, biliary tract cancer, and colorectal cancer. ClinicalTrials.gov. Updated March 13, 2025. Accessed July 1, 2025. https://tinyurl.com/y9d77aay
Part 2 of the Dress to Impress Summer Update 2025 is here, and it brings new masculine faces, new clothes, custom makeup, and plenty more. However, the planned quest for this part of the update has been temporarily delayed. With that said, this page lists everything added in part 2 of the DTI Summer Update that released on July 5, 2025, including the official DTI patch notes.
DTI Summer Update 2025 (Part 2) Patch Notes
Below are the Dress to Impress Summer Update (Part 2) patch notes, via the official Discord:
2x Stars Weekend! (until Monday at 11am EST)
7 Masc Faces
1 Fem Face
New Cardigan
New Gym Baddie Shirt
New Leather Jacket
New Tied Masc Shirt
New Collared Shirt
20 Custom Makeup Additions
New Influencer Code Item
New Rank Reward for Fashion Maven
Secret Heels? Where!?
Meat Room Now has a Keypad… What’s the code?
Dance Minigame in Lobby to earn Seashells!
Explore the New Yacht in the Lobby!
New FREE ‘Star Baby’ Walk!
New Achievement/Daily Task!
Everything Added in the Dress to Impress Summer Update 2025 (Part 2)
Part 2 of this Dress to Impress Summer Update builds on the previous part by adding new clothes, custom makeup, a new minigame to get Seashells, and more we’ll discuss below. There’s even a keypad inside the mysterious Meat Room.
New Faces Makeup
7 new masculine faces were added alongside 1 new feminine face and 20 custom makeup additions. This includes but isn’t limited to the following faces and makeup:
New Clothing
Five new tops were added, as well as one pair of secret heels hidden in the Meat Room:
A New Minigame to Get Seashells
A new minigame was added to the lobby on top of the new yacht players can find outside. Hop onto the dance floor where seashells will appear on the floor that you’ll need to stand on to fill the party meter. Doing this with others will help make it go quicker since you can only stand on one at a time.
Other Miscellaneous Additions to DTI
In addition to the new content above, some smaller tweaks were made to Dress to Impress as well:
The hidden Meat Room now has a keypad to interact with.
Starting DTI anytime before July 12, 2025, will give you the Star Baby Walk Pack when closing a message that appears upon starting the game.
The Fashion Maven rank now has a new reward, the Fashion Maven Nails.
Players can now get the Siren Tail in addition to the Old Mermaid Tail while the summer event runs.
At least one positive consequence from Iga Swiatek’s relatively poor clay court run has been the added benefit of time. Instead of arriving for the grass court season exhausted from her efforts, for once she had additional time to train, work and adapt her game to the one surface she has yet to conquer.
Swiatek’s growing comfort at Wimbledon was reflected in her most efficient performance of the tournament so far as she dismantled the eternally dangerous Danielle Collins 6-2, 6-3 to return to the fourth round.
Swiatek, who continues to build her profile as a title contender at the All England Club, will next face the 23rd seed Clara Tauson of Denmark. Tauson upset the 2022 Wimbledon champion Elena Rybakina, the 11th seed, 7-6 (6), 6-3 to reach the fourth round.
“I was just in the zone,” said Swiatek. “I knew what I wanted to play and I knew I needed to be brave and just let my hand do the job. Play fast and grab it from the beginning. You can’t let Danielle play her winners. I’m really happy with the performance because there were no ups and downs, it was pretty consistent and it was a good match.”
After winning five grand slam titles, establishing herself as the most successful player of her generation and spending most of the past few years as the world No 1, the No 8 seeding next to Swiatek’s name, which is reflective of her difficulties over the past year, looks very strange.
The 24-year-old has still not won a title at any level since the 2024 French Open last June and she has been open about how her perfectionism, one of her biggest strengths, has been her biggest weakness in recent months, often leading to her becoming overwhelmed by her negative thoughts on the court.
Iga Swiatek and Danielle Collins have had their differences in previous meetings. Photograph: Toby Melville/Reuters
Even though she was unable to win a fourth consecutive French Open title last month, Roland Garros appeared to mark a turning point for Swiatek as she finally stopped overthinking and began to play with greater freedom again. After putting together a series of positive performances to reach the semi-finals, Swiatek left Paris after her defeat to Aryna Sabalenka feeling as if she had regained her confidence on the court.
While an exhausted Swiatek would usually prioritise rest in the aftermath of her four triumphs at Roland Garros, often returning home to Poland for a few days and then playing catch up for the rest of the grass court season, this year Swiatek headed straight to Mallorca for grass court prep.
Her run to the final Bad Homburg on the eve of the Championships, both her first final of the year and her first final on grass, represented another positive result despite her eventual defeat to Jessica Pegula. She has spent her first few matches at Wimbledon attempting to further build momentum and confidence.
“Honestly, it’s much more fun this year,” said Swiatek. “I had some practices where the ball was listening to me, which was pretty new on grass. I’m just looking for that feeling for the matches as well and today was a good day. In Bad Homburg, I played many good matches so for sure, I’m getting confidence. It’s a new experience feeling good on the grass.”
skip past newsletter promotion
after newsletter promotion
There was, of course, plenty of subtext to this match-up. Last year at the Olympic Games in Paris, the pair had an extended conversation while shaking hands at the net following Collins’ retirement from their quarter-final match. Collins later revealed that she had called Swiatek “insincere” during their handshake, the sympathy Swiatek had expressed fake. In general, Collins has made it clear that she does not care for Swiatek. In May, Collins was also responsible for one of Swiatek’s worst clay-court losses in recent years as she defeated the Pole in their third-round match at the Italian Open.
Iga Swiatek served brilliantly during her victory. Photograph: Mike Hewitt/Getty Images
This time, however, the American had no response to an excellent performance. Swiatek served brilliantly, winning 86% of points behind her first serve throughout the match. Despite holding on to only one break for most of the second set, she continued to march through her service games with ease and she did not lose her serve all match.
On her groundstrokes, Swiatek also struck her forehand brilliantly, constantly using it to dominate the baseline exchanges. She showed her increased comfort with her movement by effortlessly soaking up Collins’ and forcing errors from the American with her defence.
With her spinny forehand, her preference for slower surfaces that afford her more time on the ball, her serving struggles and the general challenge of moving well on grass, there are countless reasons why Swiatek has struggled to produce her best on this surface. However, many different players and playing styles are capable of thriving on these more forgiving modern courts. Sometimes you just need time.
George Russell has admitted that he “would have definitely taken” fourth on the grid for Sunday’s British Grand Prix when heading into Qualifying, after his and the team’s difficult start to the weekend.
Russell and Mercedes were off the pace across Friday’s pair of practice sessions in pleasant, warm conditions at Silverstone, but returned to the sharp end when temperatures cooled on Saturday.
A stellar last Qualifying lap saw Russell come away with a second-row grid slot, behind Red Bull’s Max Verstappen and the two McLaren drivers, and just ahead of Ferrari duo Lewis Hamilton and Charles Leclerc – 0.229s covering that top-six group.
Asked to reflect on Qualifying, Russell said: “It was an amazing final lap. Every lap today we were… every lap this whole weekend we’ve been about five-tenths, six-tenths off the pace, sometimes even eight-tenths off the pace.
“Getting through Q1 and Q2 was a struggle, and then to finish my last lap only a tenth off pole, 20 milliseconds from the front row, I mean, yeah, I would have definitely taken it!”
With similar conditions expected on race day, Russell feels he is firmly in the mix for a podium on home soil, if not more – but reckons there could be half a dozen cars vying for the big prize.
“I think we can definitely push for a podium,” he continued. “Obviously the conditions are favourable, but it’s taken us from being off the pace to sort of being there or thereabouts – it hasn’t sort of propelled us to the front.
“I think it’s probably fair to say that we overachieved a little bit today, especially in terms of the gaps, we definitely overachieved. Ferrari obviously struggled on that last lap. Tomorrow’s probably going to be a six-way fight.”
As for Russell’s team mate, Kimi Antonelli, the Italian was some three-tenths slower en route to seventh position – but he will drop three places on Sunday due to the penalty he picked up for clashing with Max Verstappen in Austria.
“It was quite tight out there,” he said of Qualifying. “I’ve been struggling a little bit in the high speed, just struggling to feel the stability and it just killed a bit the confidence, to be honest, throughout the session.
“Not easy, but obviously tomorrow with the penalty we’ll try to do our best from there and build from there.”
Pushed on what’s still possible, Antonelli added: “Well, hopefully the race pace is going to be good. It’s not going to be easy because it’s pretty tight, but I think if we have a good start and play it smart then we can try to set a good pace and move forward.”
Ollie Bearman has branded his mistake in final practice, which earned the Haas driver a 10-place grid penalty for the British Grand Prix as “silly” and “dumb” having then achieved his best Qualifying result.
The Briton, who will compete in his home Grand Prix for the first time this weekend, showed impressive pace at Silverstone on Saturday, eventually setting the eighth fastest lap, which was his best F1 Qualifying performance to date.
But the 20-year-old will start towards the back of the grid having suffered an unusual incident in the final practice session earlier in the morning, losing control of his Haas and hitting the wall on the entry to the pits.
The collision, which ripped the front wing from his car, took place under red flag conditions after Gabriel Bortoleto’s accident left his Kick Sauber stranded.
The stewards noted that Bearman “did not drive slowly back to the pit lane” and did not consider cold tyres and brakes to be “a mitigating factor”, as he was slapped with the grid penalty and four penalty points.
When asked about the penalty in the wake of his strong Qualifying performance, Bearman told Sky Sports F1: “It sucks. Quite honestly it’s horrible, but I can only blame myself for that. It was my fault and a very silly error this morning.
“On the other hand I’m really glad we had a good Qualifying. First of all, to validate the team’s hard work because we brought an upgrade this weekend and we were in Q3 on merit, so that’s great.
“Qualifying has been our weak point for the past couple of events and now to be in Q3 on a track where there’s lots of high-speed, which across the season has not been our strongest feature, is a great feeling. I know I’m going to start from last tomorrow but I’ll see what I can do.”
The 10-place grid drop is the second such penalty for Bearman this season, after the Haas driver passed Carlos Sainz’s Williams under red flag conditions during a practice session for the Monaco Grand Prix.
Bearman so far has scored points in three races this term, with the last one coming in Bahrain back in April.
“We were doing a very slow lap during the red flag and then coming into the pit entry with very cold tyres and brakes I didn’t really account for that,” said Bearman on the incident in final practice.
“Just a silly, dumb error because when I hit the brakes they were stone-cold and so were the tyres and I lost it. Silly and really kicking myself. I wish I could go back and change it but we can’t so let’s learn from it and hopefully we can have a good race.”
WhatsApp is working on a brand-new feature for iPhone users that will make it easier to find and manage unsent messages, according to a report by WhatsApp Beta Info.
The upcoming feature, titled ‘Search for Draft Messages’, will allow users to quickly locate messages they started typing but never sent, eliminating the need to scroll through long chat lists.
Once rolled out, the feature will introduce a dedicated draft message filter within the Chats tab, giving users a clear view of all their incomplete conversations in one place. The move is aimed at improving usability and ensuring users can easily resume half-written thoughts or unsent replies without digging through old threads.
While there’s no official release date yet, sources suggest the feature is already under active development and will be part of a future iOS update.
Earlier on June 10, 2025, reports indicated that a similar feature was in the works for Android users, and iPhone users will soon enjoy the same convenience once the feature is finalised.
With this update, WhatsApp continues its push to enhance the user experience by making communication more seamless and accessible, especially for those who live in the land of half-typed, never-sent messages.
The use of trifluridine/tipiracil (Lonsurf) led to a numerical but not statistically significant improvement in disease-free survival (DFS) compared with placebo following curative resection in patients with colorectal cancer (CRC) who were positive for circulating tumor DNA (ctDNA), according to data from the phase 3 ALTAIR trial (NCT04457297).
Findings presented at the 2025 ESMO Gastrointestinal Cancers Congress revealed that in the overall population, patients treated with trifluridine/tipiracil (n = 122) achieved a median DFS of 9.30 months (7.92-10.84) compared with 5.55 months (95% CI, 4.17-7.33) in those given placebo (n = 121; HR, 0.79; 95% CI, 0.60-1.05; P = .107). In the trifluridine/tipiracil arm, the 12- and 24-month DFS rates were 31.8% (95% CI, 23.6%-40.2%) and 16.9% (95% CI, 10.4%-24.8%), respectively. These respective rates were 26.8% (95% CI, 19.16%-35%) and 14.5% (95% CI, 7.85%-23.1%) in the placebo arm.
“A [forest plot] analysis showed that patients with stage IV disease or microsatellite stable [MSS] status derived significant benefit from trifluridine/tipiracil,” lead study author Masahito Kotaka, MD, PhD, of Sano Hospital in Hyogo, Japan, said in a presentation of the data.
ALTAIR Overview
ALTAIR was part of the CIRCULATE Japan trial schema, and it included patients from the GALAXY (UMIN000039205) and VEGA trials who underwent curative resection for CRC and tested positive for ctDNA after surgery. Patients needed to be at least 20 years of age with no radiographic evidence of disease, and they received standard perioperative therapy. ctDNA monitoring was done using the Signatera assay.
Patients who tested positive for ctDNA were randomly assigned 1:1 to receive trifluridine/tipiracil or placebo for 6 cycles.
DFS served as the primary end point of ALTAIR. Secondary end points included ctDNA clearance rate, overall survival, safety, treatment completion rate, and quality of life (QOL).
Baseline characteristics were well balanced between the 2 arms. In the overall population of ALTAIR (n = 243), most patients were under 70 years of age (64%), male (58%), had left-sided tumors (71%), were ctDNA positive at 1 month following surgery (53%), had BRAF wild-type disease (96%), had RAS wild-type disease (61%), and had MSS disease (98%).
Disease stage at baseline comprised stage I (4.1%), stage II (24%), stage III (45%), and stage IV (27%). Thirty-six percent of patients received neoadjuvant therapy, and 46% underwent adjuvant treatment. Twenty-four percent of patients enrolled during the minimal residual disease window, defined as 2 to 10 weeks after surgery and prior to the start of adjuvant therapy; patients also enrolled while receiving adjuvant therapy (14%) and during surveillance (63%).
Additional DFS and ctDNA Data
In patients with stage IV disease, the median DFS was 9.76 months (95% CI, 7.62-11.76) in the trifluridine/tipiracil arm (n = 34) vs 3.96 months (95% CI, 3.71-7.98) for those in the placebo group (n = 32; HR, 0.53; 95% CI, 0.32-0.87; P = .012). In those with stage I to III disease, the median DFS was 9.27 months (95% CI, 7.62-10.97) and 6.05 months (95% CI, 4.63-9.23) for trifluridine/tipiracil (n = 88) and placebo (n = 89), respectively (HR, 0.86; 95% CI, 0.61-1.2; P = .375).
In the overall population, the rates of conversion to ctDNA negativity were 17.2% (95% CI, 11.0%-25.1%) in the trifluridine/tipiracil arm vs 12.4% (95% CI, 7.1%-19.6%) in the placebo group (odds ratio, 1.469; 95% CI, 0.718-3.008; P = .367). Conversion to ctDNA negativity was defined as a negative test at the first post-treatment assessment.
Safety and QOL Data
Any-grade adverse effects (AEs) occurred in 98.4% of patients in the trifluridine/tipiracil arm vs 57.0% of patients in the placebo group. The rates of grade 3 or higher AEs were 73.0% and 3.3%, respectively. Serious AEs and AEs leading to study discontinuation occurred in 4.9% and 6.6% of patients in the trifluridine/tipiracil arm, respectively. These rates were both 0% in the placebo arm. No patients in either group experienced AEs leading to death.
Any-grade AEs of note consisted of decreased neutrophil count (trifluridine/tipiracil, 74.6%; placebo, 4.1%), decreased white blood cell count (63.9%; 3.3%), decreased platelet count (12.3%; 3.3%), and decreased lymphocyte count (8.2%; 0.8%). In the trifluridine/tipiracil arm, the rates of these AEs occurring at grade 3 or higher were 56.6%, 17.2%, 1.6%, and 4.1%, respectively. None of these AE were reported at grade 3 or higher in the placebo arm.
AEs led to dose skipping in 95.1% of patients in the trifluridine/tipiracil arm vs 11.6% of patients in the placebo group. The rates of AEs leading to dose reductions were 37.7% and 0.8%, respectively. The median treatment duration was 174 days (range, 8-251) in the trifluridine/tipiracil arm vs 150 days (range, 40-187) in the control arm.
Regarding QOL, Kotaka noted that EORTC QLQ-C30 scores dropped during treatment, and a significant decrease in global health status occurred at week 8 in the trifluridine/tipiracil group (P = .028). No significant differences were reported between the arms following treatment from week 24 and beyond.
Disclosures: Kotaka reported receiving honoraria from Chugai Pharmaceuticals, Takeda Pharmaceuticals, and Eli Lilly.
Reference
Kotaka M, Bando H, Watanabe J, et al. Association of ctDNA clearance with disease-free survival, safety, and quality of life from ctDNA-directed therapy: Findings from the ALTAIR study. Presented at: 2025 ESMO Gastrointestinal Cancers Congress; July 2-5, 2025; Barcelona, Spain. Abstract 3O.
Britain is re-establishing diplomatic relations with Syria after the country’s years-long civil war, the foreign secretary, David Lammy, has announced during a visit to the capital, Damascus.
“There is renewed hope for the Syrian people,” Lammy said in a statement. “It is in our interests to support the new government to deliver their commitment to build a stable, more secure and prosperous future for all Syrians.”
Lammy’s visit to Syria is the first by a British minister in 14 years and is accompanied by a pledge of £94.5m for urgent humanitarian aid and to support the country’s long-term recovery and help countries hosting Syrian refugees in the region.
The west has been slowly resetting its approach to Syria since insurgent forces led by the Islamist Hayat Tahrir al-Sham ousted Bashar al-Assad as president in December after more than 13 years of war.
Just days ago, the US president, Donald Trump, signed an executive order terminating a US sanctions programme on Syria, ending its isolation from the international financial system and helping it rebuild after the war.
Britain also eased its sanctions in April, unfreezing the assets of Syria’s central bank and 23 other entities, including banks and oil companies to encourage investments, though it kept in place those targeting members of the former regime.
A stable Syria will reduce the risk of “irregular migration”, ensure chemical weapons are destroyed, and tackle the threat of terrorism, Lammy said, after meeting his Syrian counterpart, Asaad Hassan al-Shaibani, and the president, Ahmed al-Sharaa.
In those meetings, Lammy reiterated the importance of an “inclusive and representative political transition” in Syria and offered Britain’s continued support, the statement said.
skip past newsletter promotion
after newsletter promotion
Lammy is also due to travel to Kuwait, where regional security and strengthening bilateral relations will be top of the agenda. In addition, he is expected to announce a new partnership with the Gulf monarchy to tackle the humanitarian crisis in Sudan.
